ATRA Quote, Financials, Valuation and Earnings

Clearside Biomedical has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of -740.66%. Atara Biotherapeutics's return on equity of -- beat Clearside Biomedical's return on equity of --.

Atara Biotherapeutics has a consensus price target of $16.33, signalling upside risk potential of 22.53%. On the other hand Clearside Biomedical has an analysts' consensus of -- which suggests that it could grow by 545.86%. Given that Clearside Biomedical has higher upside potential than Atara Biotherapeutics, analysts believe Clearside Biomedical is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.554, which suggesting that the stock is 44.642% less volatile than S&P 500. In comparison Clearside Biomedical has a beta of 2.292, suggesting its more volatile than the S&P 500 by 129.225%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearside Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Clearside Biomedical pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Clearside Biomedical quarterly revenues of $1M. Atara Biotherapeutics's net income of -$21.9M is lower than Clearside Biomedical's net income of -$7.7M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Clearside Biomedical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.78x versus 8.49x for Clearside Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

Corvus Pharmaceuticals has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of --. Atara Biotherapeutics's return on equity of -- beat Corvus Pharmaceuticals's return on equity of --.

Atara Biotherapeutics has a consensus price target of $16.33, signalling upside risk potential of 22.53%. On the other hand Corvus Pharmaceuticals has an analysts' consensus of $15.75 which suggests that it could grow by 221.43%. Given that Corvus Pharmaceuticals has higher upside potential than Atara Biotherapeutics, analysts believe Corvus Pharmaceuticals is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.554, which suggesting that the stock is 44.642% less volatile than S&P 500. In comparison Corvus Pharmaceuticals has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.936%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Corvus Pharmaceuticals pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Corvus Pharmaceuticals quarterly revenues of --. Atara Biotherapeutics's net income of -$21.9M is higher than Corvus Pharmaceuticals's net income of -$40.2M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Corvus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.78x versus -- for Corvus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Jaguar Health has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of -317.05%. Atara Biotherapeutics's return on equity of -- beat Jaguar Health's return on equity of -394.73%.

Atara Biotherapeutics has a consensus price target of $16.33, signalling upside risk potential of 22.53%. On the other hand Jaguar Health has an analysts' consensus of $14.50 which suggests that it could grow by 482.52%. Given that Jaguar Health has higher upside potential than Atara Biotherapeutics, analysts believe Jaguar Health is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.554, which suggesting that the stock is 44.642% less volatile than S&P 500. In comparison Jaguar Health has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.646%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jaguar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Jaguar Health pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Jaguar Health quarterly revenues of $3.1M. Atara Biotherapeutics's net income of -$21.9M is lower than Jaguar Health's net income of -$9.9M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Jaguar Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.78x versus 0.38x for Jaguar Health. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of -27.76%. Atara Biotherapeutics's return on equity of -- beat Quanterix's return on equity of -11.45%.

Atara Biotherapeutics has a consensus price target of $16.33, signalling upside risk potential of 22.53%. On the other hand Quanterix has an analysts' consensus of $21.80 which suggests that it could grow by 107.22%. Given that Quanterix has higher upside potential than Atara Biotherapeutics, analysts believe Quanterix is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.554, which suggesting that the stock is 44.642% less volatile than S&P 500. In comparison Quanterix has a beta of 1.300, suggesting its more volatile than the S&P 500 by 29.975%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Quanterix quarterly revenues of $34.1M. Atara Biotherapeutics's net income of -$21.9M is lower than Quanterix's net income of -$9.5M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.78x versus 3.12x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.